Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

NCT00281957 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

109

Enrollment

NIH

Sponsor class

Conditions

Recurrent Melanoma
Stage IV Melanoma

Interventions

DRUG: sorafenib tosylate
DRUG: tipifarnib
DRUG: temsirolimus

Sponsor

National Cancer Institute (NCI)